admin

Por Rachel Lutz Los riesgos de morir por el nuevo coronavirus (COVID-19) incluyen el sexo masculino, tener ingresos y nivel de educación más bajos y nacer en el extranjero en un país de ingresos bajos o medios, según un artículo sueco publicado en Nature Communications . Los investigadores de la Universidad de Estocolmo en Suecia utilizaron los datos de todas las […]

Por Marcela Ramos universidad de Glasgow Latinoamérica tuvo tiempo para prepararse y enfrentar bien la pandemia. Pero sus condiciones estructurales en economía, vivienda y salubridad terminaron haciendo que el continente se transformara en un lugar propicio para la propagación del COVID-19. Así lo sugiere la investigación Respuestas al COVID-19 en cinco países de Latinoamérica, que revisó los

Dr. Javier Cotelo The Spanish Society of General Practitioners and Family Physicians (SEMG), in collaboration with the patient associations Long Covid ACTS, is developing a new basic care kit for patients with long COVID-19. This kit will serve as an advance guide for physicians and will support those affected by this form of the disease until further notice.

In March of this year, faced with the growing threat of Covid-19, the WHO launched a large-scale, randomized, international, open-label study called Solidarity, involving hospitalized patients, to investigate the effects of four drugs on hospital mortality. Hydroxychloroquine was declared ineffective on June 18, and lopinavir/ritonavir was also deemed ineffective.

The organization's Director of Emergencies recommended that authorities in the region monitor the health of tourists "during the first 14 days of their stay," but not require them to isolate. The Pan American Health Organization (PAHO) considers it unnecessary to require COVID-19 tests or quarantines for the resumption of travel.

Patients hospitalized with severe COVID-19 who received cyclosporine significantly reduced their risk of death, according to a retrospective study. By Sonia Moreno. A veteran of the pharmacological formulary, cyclosporine could be the next treatment for COVID-19, if the findings of a study conducted at the Quirónsalud University Hospital in Madrid are confirmed. The Department of Medicine

Two studies published in the journal Blood Advances suggest that people with blood type O may have a lower risk of Covid-19 infection and a lower likelihood of severe outcomes, including organ complications, if they do become ill. Meanwhile, people with blood types A and AB may have a higher risk of severe clinical outcomes. The potential role of blood type in predicting the risk and complications of Covid-19 is under investigation.

By Amanda D'Ambrosio, Staff Writer, MedPage Today. Coronavirus cases are surging across the U.S. Midwest, with states like Illinois, Indiana, Michigan, Nebraska, and Wisconsin experiencing a 25% increase in cases over the past 14 days. (NBC News) As of Thursday at 8:00 a.m. EST, the

Liz Highleyman: Professor Chloe Orkin presents at HIV Glasgow 2020. A combination of two long-acting injectable antiretrovirals taken once a month maintained viral suppression with a very low rate of virological failure, according to results from two phase III trials presented at the virtual Glasgow HIV conference.

Gus Cairns13 At the virtual HIV Glasgow 2020 conference, two human studies of a new drug being developed by Merck & Co. in the non-nucleoside reverse transcriptase inhibitor (NNRTI) class were discussed. This drug, MK-8507, could be administered only once a week, according to these studies. Merck already has one drug,